Advertisement

5 Responses

  1. Andrea
    Andrea May 6, 2013 at 6:40 am | | Reply

    Thanks, Mike, for the update! Sounds like it was a whirlwind but productive visit. Feeling a bit lukewarm about the glucagon update (thanks for asking!) I would have though that one of the big pharma companies would have swooped in on the Glucapen by now. Outside of technology advances, it’s something I’ve been really hopeful about.

    I would have never imagined it being so difficult with so many check marks required to put the books online. Wish this was required of the books/magazines we see in stores and at rest areas claiming cures with diet and otherwise.

    I completely agree with the two-way conversation. We can find product information at the website. While that is important, I also have the need to feel as though they just aren’t our supplier but a partner in our care. I guess accessibility and being personable over being just a corporate nature.

  2. Bill Woods
    Bill Woods May 6, 2013 at 7:17 am | | Reply

    Mike thanks as always for you in depth article and “tour” of the summit at Lilly.

    Thanks for sharing the process with others.

  3. Scott Strumello
    Scott Strumello May 6, 2013 at 8:01 am | | Reply

    While I think Drs. David Moller and David Kendall’s comment that smart, glucose-responsive insulin is “aspirational and over-hyped on timeline,” and that faster-acting insulin is what’s next in the coming years is correct, and JDRF’s own team said much the same thing in New York last month, I think there’s a degree of CYA going on from Lilly, too. The fact is, Lilly doesn’t have anything in its pipeline for Glucose Responsive Insulin (indeed, it didn’t have anything for basal insulin, either, but partnered with Boehringer Ingelheim to bring one into its portfolio, but even that might be a bit late as biosimilar versions of Sanofi’s Lantus are very likely to emerge by the time that gets approval, raising questions as to whether Lilly will have much success in the new basal product). Hence, its easy to say something is overhyped when you aren’t doing anything in the space. As for faster analogues, again, Lilly is now playing catch-up to companies like Biodel and Halozyme which are likely to modify Lilly’s insulin lispro, making it even faster using Lilly’s own product as the basis (keep in mind, most of the patents for Humalog expire in 2014). However, since 2009, they’ve had a new exec in charge of Lilly Diabetes, Enrique Conterno, who seems to comprehend that the company had for too long rested on old laurels and failed to keep up with rivals like Novo Nordisk, and is now making the investments to ensure the company remains a player in the space. U-200 Humalog is next for insulin resistant type 2s. A key question we should be asking is “what too Lilly so long to get its diabetes house in order”?

  4. Lisa
    Lisa May 11, 2013 at 8:41 am | | Reply

    Thanks for asking Lilly about the Pendiq digital insulin pen. I don’t qualify for a pump yet I am insulin sensitive and the ability to dose in 0.1U increments would be totally awesome. Plus having a record of your doses would help. Oh we’ll, I guess I’ll just wait to see who is first to market one in the US.

    It’s sad that this device is being used overseas and no one seems to be able get one approved here in the United States…

Leave a Reply